BIODESIX INC
About BIODESIX INC
Biodesix Inc is a diagnostic solutions company with a focus on lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources: providing diagnostic testing services associated with blood-based lung and COVID tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties, as well as the development and commercialization of companion diagnostics.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $88.5M
- Net income
- -$35.3M
- Total assets
- $87.5M
- Market cap
- $160.1M
- Operating margin
- -31.5%
- Net margin
- -39.8%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $88.5M
- Operating expenses
- $116.4M
- Operating income
- -$27.9M
- Income tax
- $0
- Net income
- -$35.3M
- EPS (basic)
- $-4.67
- EPS (diluted)
- $-4.67
Balance sheet
- Total assets
- $87.5M
- Current assets
- $32.5M
- Total liabilities
- $89.9M
- Current liabilities
- $17.4M
- Shareholders’ equity
- -$2.5M
Cash flow
- Operating cash flow
- -$23.3M
- Investing cash flow
- -$403.0K
- Financing cash flow
- $16.4M
- Net cash flow
- -$7.3M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $160.1M
- EPS (diluted)
- $-4.67
- Shares outstanding
- 10.7M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Oct 28, 2020
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $35.3M in FY2025.
- Revenue grew 94% from FY2020 to FY2025.
- Trading 23% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review BIODESIX INC.
Write a review
News about BIODESIX INC
News & sentiment via Polygon.io
